SKYRIZI®
Risankizumab (ABBV-066) is an anti-IL-23 antibody approved for the treatment of multiple inflammatory diseases, including psoriasis, psoriatic arthritis, and Crohn's disease. It is also being investigator for the treatment of ulcerative colitis.
Type of Molecule
BiologicTarget
IL-23Product Type
New Indication| Potential Indication | Region | Phase (1, 2, 3, Submitted) |
|---|---|---|
| Crohn's Disease | US - Approved,EU - Submitted |
Approved
|
| Psoriatic Arthritis | US,EU |
Approved
|
| Psoriasis | US,EU |
Approved
|
| Ulcerative Colitis | n/a |
Phase 3
|
SKYRIZI®
Risankizumab (ABBV-066) is an anti-IL-23 antibody approved for the treatment of multiple inflammatory diseases, including psoriasis, psoriatic arthritis, and Crohn's disease. It is also being investigator for the treatment of ulcerative colitis.
Type of Molecule
BiologicTarget
IL-23Product Type
New Indication| Potential Indication | Region | Phase (1, 2, 3, Submitted) |
|---|---|---|
| Crohn's Disease | US - Approved,EU - Submitted |
Approved
|
| Psoriatic Arthritis | US,EU |
Approved
|
| Psoriasis | US,EU |
Approved
|
| Ulcerative Colitis | n/a |
Phase 3
|